REPLIMUNE GROUP, INC. Cash and Cash Equivalents, Period Increase (Decrease)
REPLIMUNE GROUP, INC. (REPL) reported Cash and Cash Equivalents, Period Increase (Decrease) of $6.81 million for the 6-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-11-14
- REPLIMUNE GROUP, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $9.70M, a 81.22% decline year-over-year.
- REPLIMUNE GROUP, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$2.90M.
- REPLIMUNE GROUP, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $51.65M.
- REPLIMUNE GROUP, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$4.63M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month |
|---|---|---|
| 2018-09-30 | $9.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-14 | $6.81M 10-Q · filed 2018-11-14 |
| 2018-06-30 | -$2.90M 10-Q · filed 2018-08-30 | |
| 2017-09-30 | $51.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-14 | $47.02M 10-Q · filed 2018-11-14 |
| 2017-06-30 | -$4.63M 10-Q · filed 2018-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |